Bio Palette Co., Ltd.

Bio Palette Co. , Ltd. is a biotechnology firm based in Kobe, Japan, specializing in microbiome therapeutics through innovative genome-editing technologies that enhance human health. Founded in 2017 in Kobe, Japan, Bio Palette Co.

, Ltd. focuses on developing microbiome therapeutics. The company raised JPY 1 billion in Series A funding from JAFCO Group on September 24, 2020. Ryo Okumura, the CEO, leads the company, which has successfully completed two funding rounds and achieved a current valuation of JPY 4,589.

904 million. Bio Palette Co. , Ltd. specializes in microbiome therapeutics, utilizing genome-edited bacteria to modify and control microbiomes.

The company's core products leverage innovative base editing technologies, specifically Target-AID® and Target-G®, enabling precise manipulation of bacterial genetics without causing DNA double-strand breaks. This non-cutting genome editing approach enhances the efficacy of bacteria used in therapies aimed at improving human health by addressing conditions linked to microbiome imbalances. Bio Palette primarily serves the healthcare sector, targeting pharmaceutical companies and research institutions globally, particularly in North America, Europe, and Asia, where the demand for advanced microbiome treatments is rapidly growing. In 2021, Bio Palette Co.

, Ltd. reported a revenue of JPY 118. 4 million. The company generates revenue through partnerships and licensing agreements for its proprietary base editing technologies.

Engaging in B2B transactions, Bio Palette collaborates with pharmaceutical companies and research institutions that integrate its innovative solutions into therapeutic developments, deriving income from exclusive licensing deals and collaborative partnerships that may involve milestone payments based on specific research goals. Bio Palette Co. , Ltd. has plans to utilize the JPY 1 billion raised in Series A funding to support various research and development initiatives focused on microbiome treatments, which represent a new treatment modality.

The funds will also facilitate personnel increases in research departments and the expansion of research facilities. The company aims to design and launch new products targeting specific conditions linked to microbiome imbalances while expanding its reach into North American, European, and Asian markets through strategic partnerships and research collaborations.